Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nasdaq  >  Vanda Pharmaceuticals Inc.    VNDA

Delayed Quote. Delayed  - 09/28 10:00:00 pm
16.7 USD   -0.77%
09/24 VANDA PHARMACEU : Prepares to Explore a Sale – Sources
09/17 VANDA PHARMACEU : USPTO Dismisses Petition for Inter Partes Review o..
08/31 VANDA PHARMACEU : USPTO Dismisses Petition for Inter Partes Review o..
 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
09/22/2016 09/23/2016 09/26/2016 09/27/2016 09/28/2016 Date
16.62(c) 16.81(c) 17.05(c) 16.83(c) 16.7 Last
3 229 472 2 476 041 1 115 140 878 914 949 894 Volume
+6.81% +1.14% +1.43% -1.29% -0.77% Change
More quotes
Financials ($)
Sales 2016 147 M
EBIT 2016 -31,2 M
Net income 2016 -25,9 M
Debt 2016 -
Yield 2016 -
Sales 2017 184 M
EBIT 2017 -1,08 M
Net income 2017 6,23 M
Debt 2017 -
Yield 2017 -
P/E ratio 2016 -
P/E ratio 2017
Capi. / Sales2016 4,97x
Capi. / Sales2017 3,96x
Capitalization 728 M
More Financials
Company
Vanda Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of products for the treatment of central nervous system disorders.Its products portfolio includes HETLIOZ, Fanapt and Tradipitant, Trichostatin and AQW051.Vanda Pharmaceuticals was founded by... 
More about the company
Surperformance© ratings of Vanda Pharmaceuticals Inc.
Trading Rating : Investor Rating :
More Ratings
Latest news on VANDA PHARMACEUTICALS INC.
09/24 VANDA PHARMACEUTICALS : Prepares to Explore a Sale – Sources
09/22 VANDA PHARMACEUTICALS : Assigned Patent
09/17 VANDA PHARMACEUTICALS : USPTO Dismisses Petition for Inter Partes Review of Fana..
08/31 VANDA PHARMACEUTICALS : USPTO Dismisses Petition for Inter Partes Review of Fana..
08/30 VANDA PHARMACEUTICALS : USPTO Dismisses Petition for Inter Partes Review of Fana..
08/26 WHERE THINGS STAND FOR VANDA PHARMAC : VNDA) In Fanapt Patent Suit
08/26 VANDA PHARMACEUTICALS : Patents Found Valid and Infringed in Fanapt ANDA Litigat..
08/25 VANDA PHARMACEUTICALS INC. : Other Events, Financial Statements and Exhibits (fo..
08/25 VANDA PHARMACEUTICALS : Patents Found Valid and Infringed in Fanapt® ANDA Litiga..
08/23 VANDA PHARMACEUTICALS : HETLIOZ Now Available for Treatment of Non-24-Hour Sleep..
More news
Sector news : Bio Therapeutic Drugs
09/27DJAMGEN : Myeloma Treatment Study Fails to Meet Primary Endpoint
09/26DJPfizer Throws Out Plan to Split Into Two Companies
09/26DJSANOFI : FDA Accepts Sanofi's, Regeneron's Dermatitis Treatment for Priority Rev..
09/23DJAMGEN : FDA Approves Amgen's Biosimilar Version of Humira -- 2nd Update
09/23DJAMGEN : FDA Approves Amgen's Biosimilar Version of Humira -- Update
More sector news : Bio Therapeutic Drugs
News from SeekingAlpha
09/26 BIOTECH FORUM DAILY DIGEST : Behind Some Big Moves In Small Caps. Spotlight On V..
09/20 INSIDERINSIGHTS.COM DAILY ROUND UP 9 : Phillips 66, Nuveen Global Equity Income ..
08/31 VANDA : Fanapt Patent Ruling Adds To Upside Potential
08/28 Why Recent Fanapt Ruling Is Important To Vanda
08/26 BIOTECH FORUM DAILY DIGEST : Clinton Takes A Swipe At Biotech, Revisiting The Bu..
Advertisement
Chart VANDA PHARMACEUTICALS INC.
Duration : Period :
Vanda Pharmaceuticals Inc. Technical Analysis Chart | VNDA | US9216591084 | 4-Traders
Full-screen chart
Technical analysis trends VANDA PHARMACEUTI...
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 4
Average target price 20,0 $
Spread / Average Target 19%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Mihael Hristos Polymeropoulos President, Chief Executive Officer & Director
H. Thomas Watkins Chairman
James Patrick Kelly Chief Financial Officer, Treasurer & Senior VP
Paolo Baroldi Chief Medical Officer & Senior Vice President
Howard H. Pien Independent Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
VANDA PHARMACEUTICALS ..80.77%738
AMGEN, INC.5.73%129 863
GILEAD SCIENCES, INC.-21.68%106 391
CELGENE CORPORATION-10.32%82 402
REGENERON PHARMACEUTIC..-22.37%42 552
VERTEX PHARMACEUTICALS..-29.17%21 876
More Results